Lantern Pharma Inc.
LTRN · NASDAQ
Financial statements
Annual and quarterly income, balance-sheet, cash-flow and key-statistics data.
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2022 FY | — | — | -14.43M | -14.26M | -1.31 |
| 2023 FY | — | -174.84K | -17.88M | -15.96M | -1.47 |
| 2024 FY | — | — | -22.22M | -20.78M | -1.93K |
| 2025 FY | — | — | -17.98M | -17.12M | -1.57 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2022 FY | 58.84M | 2.80M | 37.20M | 52.89K | 56.04M |
| 2023 FY | 43.65M | 2.74M | 21.94M | 234.47K | 40.91M |
| 2024 FY | 25.57M | 4.38M | 7.51M | 243.66K | 21.19M |
| 2025 FY | 11.04M | 4.50M | 4.42M | 78.54M | 6.53M |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2022 FY | -12.77M | -27.84K | -12.80M | — | -14.78M |
| 2023 FY | -14.35M | -18.73K | -14.37M | — | -15.81M |
| 2024 FY | -17.81M | -12.60K | -17.83M | — | -14.43M |
| 2025 FY | -15.68M | -1.72K | -15.68M | — | -3.09M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2022 FY | 65.54M | 28.39M | — | — | — |
| 2023 FY | 46.41M | 24.70M | — | — | — |
| 2024 FY | 34.33M | 27.06M | — | — | — |
| 2025 FY | 33.02M | 107.14M | — | — | — |
| 2026-12-31 | — | — | — | — | — |
| 2027-12-31 | — | — | — | — | — |
| 2028-12-31 | — | — | — | — | — |
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 Q2 | — | — | -4.65M | -4.33M | -0.40 |
| 2025 Q3 | — | — | -4.35M | -4.18M | -0.39 |
| 2025 Q4 | — | — | -4.20M | -4.07M | -0.36 |
| 2026 Q1 | — | -3.85K | -3.41M | -3.33M | -0.30 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2025 Q2 | 17.42M | 4.90M | 6.06M | 145.04K | 12.52M |
| 2025 Q3 | 13.63M | 4.04M | 8.39M | 93.95K | 9.59M |
| 2025 Q4 | 11.04M | 4.50M | 4.42M | 78.54K | 6.53M |
| 2026 Q1 | 7.22M | 3.78M | 4.92M | 59.08K | 3.45M |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2025 Q2 | -3.94M | -3.00 | -3.94M | — | -316.19K |
| 2025 Q3 | -4.57M | -560.00 | -4.57M | — | 2.33M |
| 2025 Q4 | -2.79M | -1.00 | -2.79M | — | -3.97M |
| 2026 Q1 | -3.77M | -3.00 | -3.77M | — | 494.96K |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2025 Q2 | 34.08M | 28.16M | — | — | — |
| 2025 Q3 | 47.13M | 38.83M | — | — | — |
| 2025 Q4 | 33.02M | 28.68M | — | — | — |
| 2026 Q1 | 15.42M | 10.56M | — | — | — |
| 2026-06-30 | — | — | — | — | — |
| 2026-09-30 | — | — | — | — | — |
| 2026-12-31 | — | — | — | — | — |